Zaleplon — Membership Pricing

Other medications in Mental Health

• Ziprasidone
• Zuranolone
• Acamprosate
• Alprazolam
• Amphetamine Salts
• Aripiprazole
• Asenapine
• Atomoxetine

About Zaleplon

If you're experiencing difficulty falling asleep, zaleplon might be a medication your doctor prescribes for short-term relief. This medication is designed to help you initiate sleep more quickly. At TheDrugClub, we believe in making essential medications like zaleplon more affordable. Our membership program helps individuals save significantly on their prescription costs, ensuring better access to the care you need.

What is Zaleplon and What Does It Treat?

Zaleplon is a prescription medication primarily used for the short-term treatment of insomnia. Specifically, it's prescribed for individuals who have difficulty falling asleep. It's not typically used for maintaining sleep throughout the night or for long-term insomnia, as its effects are relatively short-lived. Your doctor will determine if zaleplon is the right choice for your specific sleep challenges, often recommending it as part of a broader sleep hygiene strategy.

How Does Zaleplon Work?

Zaleplon belongs to a class of drugs known as sedative-hypnotics, often referred to as 'Z-drugs.' It works by affecting certain chemicals in your brain, primarily gamma-aminobutyric acid (GABA). GABA is a neurotransmitter that helps to calm brain activity. By enhancing the effects of GABA, zaleplon helps to slow down brain function, leading to feelings of relaxation and drowsiness, which in turn helps you fall asleep more quickly. Its rapid action and short half-life mean it helps with sleep onset without typically causing significant next-day grogginess,

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Zaleplon is approved for (FDA label)

Zaleplon is indicated for the short-term treatment of insomnia. Zaleplon has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see Clinical Trials under CLINICAL PHARMACOLOGY ) . It has not been shown to increase total sleep time or decrease the number of awakenings. The clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. The final formal assessments of sleep latency were performed at the end of treatment.

Source: Read the full FDA label on DailyMed. Label effective date: October 17, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Zaleplon (FDA label)

WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of zaleplon. Some of these events may result in serious injuries, including death. Discontinue zaleplon immediately if a patient experiences a complex sleep behavior (see CONTRAINDICATIONS and Complex Sleep Behaviors under WARNINGS ) .

Source: FDA prescribing information (DailyMed). Set ID: a1277ef5-6072-43ff-a6ce-0a7cea58b7cb. SPL document ID: 415d7fa5-73ac-93e7-e063-6294a90a02a3. Label effective date: October 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Zaleplon (FDA label)

The premarketing development program for zaleplon included zaleplon exposures in patients and/or normal subjects from 2 different groups of studies: approximately 900 normal subjects in clinical pharmacology/pharmacokinetic studies; and approximately 2,900 exposures from patients in placebo-controlled clinical effectiveness studies, corresponding to approximately 450 patient exposure years. The conditions and duration of treatment with zaleplon varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, and short-term or longer-term exposure. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs. Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing.

Source: FDA prescribing information (DailyMed). Set ID: a1277ef5-6072-43ff-a6ce-0a7cea58b7cb. SPL document ID: 415d7fa5-73ac-93e7-e063-6294a90a02a3. Label effective date: October 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Zaleplon (FDA label)

Zalepon is contraindicated in patients: who have experienced complex sleep behaviors after taking zaleplon (see WARNINGS ). with hypersensitivity to zaleplon or any excipients in the formulation (see PRECAUTIONS ).

Source: FDA prescribing information (DailyMed). Set ID: a1277ef5-6072-43ff-a6ce-0a7cea58b7cb. SPL document ID: 415d7fa5-73ac-93e7-e063-6294a90a02a3. Label effective date: October 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Zaleplon (FDA label)

As with all drugs, the potential exists for interaction with other drugs by a variety of mechanisms. CNS-Active Drugs: Ethanol: Zaleplon 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration. The potentiation resulted from a CNS pharmacodynamic interaction; zaleplon did not affect the pharmacokinetics of ethanol. Imipramine: Co-administration of single doses of zaleplon 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.

Source: FDA prescribing information (DailyMed). Set ID: a1277ef5-6072-43ff-a6ce-0a7cea58b7cb. SPL document ID: 415d7fa5-73ac-93e7-e063-6294a90a02a3. Label effective date: October 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.